<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For the prevention of recurrent embolic <z:hpo ids='HP_0001297'>stroke</z:hpo>, 23 elderly patients with non-valvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (NVAF) were treated with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (<z:chebi fb="8" ids="10033">warfarin</z:chebi>) during a mean period of 3.8 years </plain></SENT>
<SENT sid="1" pm="."><plain>Only one patient suffered recurrent embolism, and another had <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>There was no cerebral haemorrhage during the treatment </plain></SENT>
<SENT sid="3" pm="."><plain>In an untreated control group (from an autopsy series), recurrent embolic <z:hpo ids='HP_0001297'>strokes</z:hpo> occurred in 18 of 70 NVAF patients (26%) during a mean period of 1.3 years </plain></SENT>
<SENT sid="4" pm="."><plain>Long-term <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy appears to be effective in the prevention of recurrent embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> in elderly patients with NVAF </plain></SENT>
</text></document>